The two-day summit, scheduled for September 29–30, features a keynote by Noel Sobelman, partner at Accel Management Group, who will explore the integration of strategy and execution. Sobelman will lead an executive panel featuring representatives from Novartis, Biogen, and Zentalis Pharmaceuticals to dissect how innovation management principles function within complex corporate structures.
Biopharma Leaders to Tackle R&D Uncertainty at 2026 EP3M Summit
As pharmaceutical firms grapple with compressed innovation cycles and mounting resource constraints, the 2026 EP3M Summit convenes in Boston this September to address the mechanics of high-stakes R&D decision-making. The twentieth-anniversary event focuses on bridging the gap between strategic intent and the realities of portfolio execution.
This year’s program introduces an interactive pre-conference workshop titled "Inside the Portfolio Committee." Led by Zentalis Pharmaceuticals’ Joe Stalder and Captario’s Magnus Ytterstad, the session utilizes simulated pharmaceutical scenarios to train participants in portfolio modeling and resource allocation. The agenda covers a broad spectrum of industry concerns, including AI-driven decision intelligence, governance models, and the optimization of portfolio value. Attendees from organizations such as AbbVie, Eli Lilly, and Sanofi will share methodologies for navigating scientific uncertainty, with early registration rates available through July 17.
Comments (0)
No comments yet. Be the first!